Potential dual role of eugenol in inhibiting advanced glycation end products in diabetes: Proteomic and mechanistic insights

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Singh, Priyanka ^a   Jayaramaiah, Ramesha H ^a   Agawane, Sachin B ^a   Vannuruswamy, Garikapati ^a   Korwar, Arvind M ^a   Anand, Atul ^a   Dhaygude, Vitthal S ^b   Shaikh, Mahemud L ^c   Joshi, Rakesh S ^d   Boppana, Ramanamurthy ^c   Kulkarni, Mahesh J ^a   Thulasiram, Hirekodathakallu V ^a,e   Giri, Ashok P ^a  

^a NATIONAL CHEMICAL LABORATORY   (India)

^b Krantisinh Nana Patil College of Veterinary Science   (India)

^c NATIONAL CENTRE FOR CELL SCIENCE   (India)

^d UNIVERSITY OF PUNE   (India)

^e CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; EUGENOL; GLUCOSE BLOOD LEVEL; GLYCOSIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; GUANIDINE DERIVATIVE; PLANT EXTRACT;

ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; OCIMUM; PRECLINICAL STUDY; PROTEOMICS;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DRUG EVALUATION, PRECLINICAL; EUGENOL; GLYCOSIDE HYDROLASE INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HEMOGLOBIN A, GLYCOSYLATED; MALE; MICE, INBRED BALB C; OCIMUM; PLANT EXTRACTS; PROTEOMICS;

EID: 84954151519     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18798     Document Type: Article

References (37)

1. Van De Laar F. A., et al. α -Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 28, 154-163 (2005
2. Scheen A. J. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diabetes Metab. 24, 311-320 (1998
3. Fukaya N., et al. The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats. Eur. J. Pharmacol. 624, 51-57 (2009
4. Matsumoto K., et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care 21, 256-260 (1998
5. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46, 223-234 (1995
6. Brownlee M. The pathobiology of diabetic complications. Diabetes 54, 1615-1625 (2005
7. Luthra M., & Balasubramanian D. Nonenzymic glycation alters protein structure and stability. J. Biol. Chem. 288, 18119-18127 (1993
8. Kulkarni M. J., Korwar A. M., Mary S., Bhonsle H. S., & Giri A. P. Glycated proteome: From reaction to intervention. Proteomics Clin. Appl. 7, 155-170 (2013
9. Vinson J. A., & Howard T. B. Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. J. Nutr. Biochem. 7, 659-663 (1996
10. Urios P., Grigorova-Borsos A. M., & Sternberg M. Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen. Diabetes Res. Clin. Pract. 77, 337-340 (2007
11. Ruggiero-Lopez D., et al. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem. Pharmacol. 58, 1765-1773 (1999
12. Kesavan S. K., et al. Proteome wide reduction in AGE modification in streptozotocin induced diabetic mice by hydralazine mediated transglycation. Sci. Rep. 3, 2941 (2013
13. Vasan S., et al. An agent cleaving glucose derived protein crosslinks in vitro and in vivo. Nature 382, 275-278 (1996
14. Mizutani K., Ikeda K., & Yamori Y. Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem. Biophys. Res. Commun. 274, 61-67 (2000
15. Tang Y. Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab. Invest. 94, 503-516 (2014
16. Raskin P., et al. Combination therapy for Type 2 diabetes: repaglinide plus rosiglitazone. Diabetic Med. 21, 329-335 (2004
17. Matsumoto K., et al. Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control. Metabolism 51, 1548-1552 (2002
18. Chiasson J. L., & Naditch L. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 24, 989-994 (2001
19. Prakash P., & Gupta N. Therapeutic uses of Ocimum sanctum Linn (Tulsi) with a note on eugenol and its pharmacological actions: a short review. Indian J. Physiol. Pharmacol. 49, 125-131 (2005
20. Hakkim F. L., Arivazhagan G., & Boopathy R. Antioxidant property of selected Ocimum species and their secondary metabolite content. J. Med. Plants Res. 2, 250-257 (2008
21. Bhargava K. P., & Singh. N. Anti-stress activity of Ocimum sanctum Linn. Indian J. Med. Res. 73, 443-451 (1981
22. Karthikeyan K., Gunasekaran P., Ramamurthy N., & Govindasamy S. Anticancer activity of Ocimum sanctum. Pharmac. Biol. 37, 285-290 (1999
23. Uma Devi P., Ganasoundari A., Vrinda B., Srinivasan K. K., & Unnikrishnan M. K. Radiation protection by the Ocimum flavanoids orientin and vicenin: mechanisms of action. Radiat. Res. 154, 455-460 (2005
24. Khan A., Ahmad A., Manzoor N., & Khan L. A. Antifungal Activities of Ocimum sanctum essential oil and its lead molecules. Nat. Prod. Commun. 5, 345-349 (2010
25. Singh P., et al. Insecticidal Potential of Defense Metabolites from Ocimum kilimandscharicum against Helicoverpa armigera. PLoS ONE 9, e104377 (2014
26. Chattopadhyay R. R. Hypoglycemic effect of Ocimum sanctum leaf extract in normal and streptozotocin diabetic rats. Indian J. Exp. Biol. 31, 891-893 (1993
27. Hannan J. M., et al. Ocimum sanctum leaf extracts stimulate insulin secretion from perfusd pancreas, isolated islets and clonal pancreatic beta-cells. J. Endocrinol. 189, 127-136 (2006
28. Bors W., & Michel C. Chemistry of the antioxidant activity of polyphenols. Ann. N Y Acad. Sci. 957, 57-69 (2002
29. Zhang M., Xu W., & Deng Y. A New Strategy for Early Diagnosis of Type 2 Diabetes Mellitus by standard-free, label-free LC-MS/MS quantification of glycated peptides. Diabetes 62, 3936-3942 (2013
30. Yanagisawa K., et al. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metabolism 47, 1348-1353 (1998
31. Kolekar Y. M., et al. Investigation of antiglycation activity of isoprenaline. RSC Adv. 5, 25051-25058 (2015
32. Elya B., et al. Screening of α -glucosidase inhibitory activity from some plants of apocynaceae, clusiaceae, euphorbiaceae, and rubiaceae. J. Biomed. Biotechnol. 2012, 1-6, doi: 10.1155/2012/281078 (2011
33. Bhonsle H. S., et al. Low plasma albumin levels are associated with increased plasma protein glycation and HbA1c in diabetes. J. Proteome Res. 11, 1391-1396 (2012
34. Cheng F. Y., Blackburn K., Lin Y. M., Goshe M. B., & Williamson J. D. Absolute protein quantification by LC/MS (E) for global analysis of salicylic acid-induced plant protein secretion responses. J. Proteome Res. 8, 82-93 (2009
35. Bhonsle H. S., et al. Zoom-ln-A targeted database search for identification of glycation modifications analyzed by untargeted tandem mass spectrometry. Eur. J. Mass Spectrom. 18, 475-481 (2012
36. Korwar A. M., et al. Development of diagnostic fragment ion library for glycated peptides of human serum albumin: Targeted quantification in prediabetic, diabetic and microalbuminuria plasma by parallel reaction monitoring, SWATH and MSE. Mol. Cell Proteomics 14, 2150-2159 (2015
37. Jones K. A., et al. Immunodepletion plasma proteomics by tripleTOF 5600 and Orbitrap elite/LTQ-Orbitrap Velos/Q exactive mass spectrometers. J. Proteome Res. 12, 4351-4365 (2013